Exicure is using its proprietary SNA technology platform to build a broad pipeline of products for a range of diseases with unmet medical need. The company's strategy is to maximize the potential of its Spherical Nucleic Acid (SNA) technology platform through in-house development, collaborations and licensing.
Exicure may also establish platform partnerships with pharmaceutical companies across multiple indications or within specific therapeutic areas.
For more information regarding Exicure's partnering strategy, please contact Gordon Beck, Ph.D., VP Business Development, gbeck at aurasense.com.
AuraSense Therapeutics Announces Publication of Preclinical Data Demonstrating Immuno-Modulation by its Proprietary Spherical Nucleic Acid Platform
C&EN News Explores Immune Modulating Capabilities of SNA Technology
Biotuesdays: In Conversation with David Giljohann
AuraSense Therapeutics Adds to Series C Financing
David Giljohann Named Among Top 40 Under 40 by Analytical Scientist